Skip to main content
SpringerLink
Log in

Intravitreale Implantate

Wirkstoff- und „Hoffnungsträger“?

Intravitreal implants

Drug carriers and carriers of hope?

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Für die Therapie der nichtinfektiösen Uveitis werden Immunsuppressiva verwendet, sofern keine ausreichende Reiz- und Rezidivfreiheit mit Steroiden in niedriger Dosierung zu erreichen ist. Hierbei werden zum Erhalt des Visus auch bei Erkrankungen, die auf die Augen beschränkt sind, zum Teil erhebliche Nebenwirkungen in Kauf genommen. Wünschenswert ist also eine Therapie, die hochwirksam ist, auf die Augen beschränkt bleibt und ein geringes Nebenwirkungspotenzial aufweist. Hierzu wurden die Fluocinolon-acetonid- und Dexamethason-Implantate entwickelt. Dexamethason-Implantate sind bereits für die Therapie von retinalen Venenverschlüssen zugelassen und werden hier erfolgreich eingesetzt. Das diabetische Makulaödem ist ein weiteres mögliches Einsatzgebiet für Dexamethason-Implantate.

Abstract

Immunosuppressive agents are used for the therapy of noninfectious uveitis if intraocular quiescence and freedom from recurrences are not achievable with oral steroids at a low dosage. Partially, severe side effects are tolerated to preserve visual acuity even if the disease is limited to the eyes. Because of this a therapy would be desirable which is highly effective, limited to the eyes and with few side effects. For this fluocinolone acetonide and dexamethasone drug delivery systems were developed. Dexamethasone implants were already approved for the therapy of retinal vein occlusions and are used successfully. Diabetic macular edema would be another possible indication for dexamethasone implants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Bordello F (2010) 12-month evaluation of dexamethasone intravitreal Implant in patients with macular edema due to central retinal vein occlusion. Abstract 560 EURETINA Paris

  2. Brown DM, Campochiaro PA, Singh RP (2010) Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133

    Article  PubMed  Google Scholar 

  3. Callanan D, Jaffe G, Martin D et al (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant. Arch Ophthalmol 126(9):1191–1201

    Article  PubMed  Google Scholar 

  4. Campochiaro PA, Heier JS, Feiner L (2010) Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112

    Article  PubMed  Google Scholar 

  5. Haller JA, Kuppermann BD, Blumenkranz MS et al (2010) Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 128(3):289–296

    Article  PubMed  CAS  Google Scholar 

  6. Haller JA, Bandello F, Belfort R et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134–1146

    Article  PubMed  Google Scholar 

  7. Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmology 18:481–486

    Article  Google Scholar 

  8. Jabs DA, Rosenabum JT, Foster CS et al (2000) Perspective: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492–513

    Article  PubMed  CAS  Google Scholar 

  9. Jaffe GJ, Martin D, Callanan D et al (2006) Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113(6):1020–1027

    Article  PubMed  Google Scholar 

  10. Kuppermann BD, Blumenkranz MS, Haller JA et al (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125(3):309–317

    Article  PubMed  CAS  Google Scholar 

  11. Kwak HW, D’Amico DJ (1992) Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110:259–266

    PubMed  CAS  Google Scholar 

  12. Lowder C, Belfort R, Lightman S (2011) Dexamethasone intravitreal implant for noninfectious intermdiate or posterior uveitis. Arch Opthalmol (published online January 10). doi: 10.1001/archophthalmol.2010.339

  13. Pavesio C, Zierhut M, Bairi K et al (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117(3):567–575

    Article  PubMed  Google Scholar 

  14. Sharma SM, Nestel AR, Lee RWJ et al (2009) Clinical review: Anti-TNFα therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 17(6):403–414

    Article  PubMed  CAS  Google Scholar 

  15. Taylor SR, Isa H, Joshi L et al (2010) New developments in corticosteroid therapy for uveitis. Ophthalmologica 224(1):46–53

    Article  PubMed  CAS  Google Scholar 

  16. Welty DF, Robinson MR, Kuppermann BD et al (2008) Pharmacokinetics of intravitreally administered dexamethasone posterior-segment drug delivery system. WOC abstract 6791

  17. Williams GA, Haller JA, Kuppermann BD et al (2009) Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 147(6):1048–1054

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Universitätsaugenklinik Charité, Virchow- Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland

    S. Winterhalter, P. Ruokonen, U. Pleyer & A.M. Joussen

  2. Universitätsaugenklinik, Düsseldorf, Deutschland

    K.H. van der Velden

Authors
  1. S. Winterhalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Ruokonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K.H. van der Velden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Pleyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A.M. Joussen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Winterhalter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winterhalter, S., Ruokonen, P., van der Velden, K. et al. Intravitreale Implantate. Ophthalmologe 108, 222–229 (2011). https://doi.org/10.1007/s00347-010-2264-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-010-2264-y

Schlüsselwörter

Keywords

Search

Navigation